ASSESS-3*: A randomised, double-blind, flexible-dose clinical trial of the efficacy and safety of oral sildenafil in the treatment of men with erectile dysfunction in Taiwan

K. K. Chen, J. T. Hsieh, S. T. Huang, D. B P Jiaan, J. S N Lin, C. J. Wang

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

The efficacy and safety of sildenafil were evaluated in a randomised, double-blind, placebo-controlled, flexible-dose study in Taiwanese men aged 26 to 80 y with erectile dysfunction (ED) of broad-spectrum aetiology and more than 6 months' duration. A total of 236 patients were randomised at six medical centres in Taiwan to receive either sildenafil (50 mg initially increased if necessary to 100 mg or decreased to 25 mg depending on efficacy and toleration) (n = 119) or matching placebo (n = 117) taken on an 'as needed' basis 1 h prior to anticipated sexual activity for a period of 12 weeks. At the end of 12 weeks, the primary efficacy variables relating to the achievement and maintenance of erections sufficient for sexual intercourse, and the secondary efficacy variables, which included: (1) the five separate domains of sexual functioning of the IIEF (International Index of Erectile Function) scale, (2) the percentage of successful intercourse attempts; and (3) a global assessment of erections, were all statistically significantly improved by sildenafil in comparison with placebo (P<0.0001). Treatment-related adverse events occurred in 43.7% of patients receiving sildenafil and 18.8% receiving placebo. The most common adverse events with sildenafil were flushing, dizziness and headache (25.2, 6.7 and 5.9% of patients, respectively), and most were mild in nature. The efficacy and safety of sildenafil in the population of Taiwanese men appears similar to that reported in other studies in western populations.

Original languageEnglish (US)
Pages (from-to)221-229
Number of pages9
JournalInternational Journal of Impotence Research
Volume13
Issue number4
DOIs
StatePublished - 2001

Fingerprint

Erectile Dysfunction
Taiwan
Clinical Trials
Safety
Placebos
Therapeutics
Coitus
Dizziness
Sexual Behavior
Population
Headache
Sildenafil Citrate
Maintenance

Keywords

  • Efficacy
  • Erectile dysfunction
  • Safety
  • Sildenafil

ASJC Scopus subject areas

  • Urology

Cite this

ASSESS-3* : A randomised, double-blind, flexible-dose clinical trial of the efficacy and safety of oral sildenafil in the treatment of men with erectile dysfunction in Taiwan. / Chen, K. K.; Hsieh, J. T.; Huang, S. T.; Jiaan, D. B P; Lin, J. S N; Wang, C. J.

In: International Journal of Impotence Research, Vol. 13, No. 4, 2001, p. 221-229.

Research output: Contribution to journalArticle

@article{2ccdaac544004141bda3ccc4c4a02dc5,
title = "ASSESS-3*: A randomised, double-blind, flexible-dose clinical trial of the efficacy and safety of oral sildenafil in the treatment of men with erectile dysfunction in Taiwan",
abstract = "The efficacy and safety of sildenafil were evaluated in a randomised, double-blind, placebo-controlled, flexible-dose study in Taiwanese men aged 26 to 80 y with erectile dysfunction (ED) of broad-spectrum aetiology and more than 6 months' duration. A total of 236 patients were randomised at six medical centres in Taiwan to receive either sildenafil (50 mg initially increased if necessary to 100 mg or decreased to 25 mg depending on efficacy and toleration) (n = 119) or matching placebo (n = 117) taken on an 'as needed' basis 1 h prior to anticipated sexual activity for a period of 12 weeks. At the end of 12 weeks, the primary efficacy variables relating to the achievement and maintenance of erections sufficient for sexual intercourse, and the secondary efficacy variables, which included: (1) the five separate domains of sexual functioning of the IIEF (International Index of Erectile Function) scale, (2) the percentage of successful intercourse attempts; and (3) a global assessment of erections, were all statistically significantly improved by sildenafil in comparison with placebo (P<0.0001). Treatment-related adverse events occurred in 43.7{\%} of patients receiving sildenafil and 18.8{\%} receiving placebo. The most common adverse events with sildenafil were flushing, dizziness and headache (25.2, 6.7 and 5.9{\%} of patients, respectively), and most were mild in nature. The efficacy and safety of sildenafil in the population of Taiwanese men appears similar to that reported in other studies in western populations.",
keywords = "Efficacy, Erectile dysfunction, Safety, Sildenafil",
author = "Chen, {K. K.} and Hsieh, {J. T.} and Huang, {S. T.} and Jiaan, {D. B P} and Lin, {J. S N} and Wang, {C. J.}",
year = "2001",
doi = "10.1038/sj.ijir.3900685",
language = "English (US)",
volume = "13",
pages = "221--229",
journal = "International Journal of Impotence Research",
issn = "0955-9930",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - ASSESS-3*

T2 - A randomised, double-blind, flexible-dose clinical trial of the efficacy and safety of oral sildenafil in the treatment of men with erectile dysfunction in Taiwan

AU - Chen, K. K.

AU - Hsieh, J. T.

AU - Huang, S. T.

AU - Jiaan, D. B P

AU - Lin, J. S N

AU - Wang, C. J.

PY - 2001

Y1 - 2001

N2 - The efficacy and safety of sildenafil were evaluated in a randomised, double-blind, placebo-controlled, flexible-dose study in Taiwanese men aged 26 to 80 y with erectile dysfunction (ED) of broad-spectrum aetiology and more than 6 months' duration. A total of 236 patients were randomised at six medical centres in Taiwan to receive either sildenafil (50 mg initially increased if necessary to 100 mg or decreased to 25 mg depending on efficacy and toleration) (n = 119) or matching placebo (n = 117) taken on an 'as needed' basis 1 h prior to anticipated sexual activity for a period of 12 weeks. At the end of 12 weeks, the primary efficacy variables relating to the achievement and maintenance of erections sufficient for sexual intercourse, and the secondary efficacy variables, which included: (1) the five separate domains of sexual functioning of the IIEF (International Index of Erectile Function) scale, (2) the percentage of successful intercourse attempts; and (3) a global assessment of erections, were all statistically significantly improved by sildenafil in comparison with placebo (P<0.0001). Treatment-related adverse events occurred in 43.7% of patients receiving sildenafil and 18.8% receiving placebo. The most common adverse events with sildenafil were flushing, dizziness and headache (25.2, 6.7 and 5.9% of patients, respectively), and most were mild in nature. The efficacy and safety of sildenafil in the population of Taiwanese men appears similar to that reported in other studies in western populations.

AB - The efficacy and safety of sildenafil were evaluated in a randomised, double-blind, placebo-controlled, flexible-dose study in Taiwanese men aged 26 to 80 y with erectile dysfunction (ED) of broad-spectrum aetiology and more than 6 months' duration. A total of 236 patients were randomised at six medical centres in Taiwan to receive either sildenafil (50 mg initially increased if necessary to 100 mg or decreased to 25 mg depending on efficacy and toleration) (n = 119) or matching placebo (n = 117) taken on an 'as needed' basis 1 h prior to anticipated sexual activity for a period of 12 weeks. At the end of 12 weeks, the primary efficacy variables relating to the achievement and maintenance of erections sufficient for sexual intercourse, and the secondary efficacy variables, which included: (1) the five separate domains of sexual functioning of the IIEF (International Index of Erectile Function) scale, (2) the percentage of successful intercourse attempts; and (3) a global assessment of erections, were all statistically significantly improved by sildenafil in comparison with placebo (P<0.0001). Treatment-related adverse events occurred in 43.7% of patients receiving sildenafil and 18.8% receiving placebo. The most common adverse events with sildenafil were flushing, dizziness and headache (25.2, 6.7 and 5.9% of patients, respectively), and most were mild in nature. The efficacy and safety of sildenafil in the population of Taiwanese men appears similar to that reported in other studies in western populations.

KW - Efficacy

KW - Erectile dysfunction

KW - Safety

KW - Sildenafil

UR - http://www.scopus.com/inward/record.url?scp=0034864622&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034864622&partnerID=8YFLogxK

U2 - 10.1038/sj.ijir.3900685

DO - 10.1038/sj.ijir.3900685

M3 - Article

C2 - 11494079

AN - SCOPUS:0034864622

VL - 13

SP - 221

EP - 229

JO - International Journal of Impotence Research

JF - International Journal of Impotence Research

SN - 0955-9930

IS - 4

ER -